Revolutionizing Pharma: Biopharmaceutical Contract Manufacturing...

Revolutionizing Pharma: Biopharmaceutical Contract Manufacturing Market Trends By 2022 to 2029

Posted 2024-01-11 09:29:54

Global Biopharmaceutical Contract Manufacturing Market was estimated to be worth roughly US$ 9.3 Billion in 2022 and is expected to grow at a CAGR of 10.5% to reach US$ 18.7 billion by 2029.

A few benefits provided by biopharmaceutical manufacturing businesses include access to pricey technologies, a shorter overall time to market investment for new pharmaceuticals, and increased flexibility. Several multinational corporations have outsourced their biopharmaceutical production operations as a result of these factors. When a biopharmaceutical company's internal production capacity is restricted, contract manufacturing for the biopharmaceutical industry is highly recommended.

Get your PDF Sample Report with Latest Market Information: https://www.futuremarketinsights.com/reports/sample/rep-gb-2982

Pharmaceutical companies prefer not to take financial risks when formulating the final dose of medicines because they primarily concentrate on their core competencies. This is likely to hasten the growth of the global biopharmaceutical contract manufacturing market, which is projected to reach a value of US$18.7 billion by 2029, over the forecast period.

Regional Insights:

The U.S. dominates the North American region with a total market share of 91.0% in 2021 and is projected to continue experiencing high growth throughout the forecast period.

Germany is set to exhibit a CAGR of over 11.5% in the European biopharmaceutical contract manufacturing market during the forecast period. In this region, the next generation therapy market is believed to be driven by biological treatment options compared to the pharmaceutical option.

China holds 34.8% share in the East Asia market in 2021 and is projected to increase at a CAGR rate of 13.5% during the forecast period. The growth of the biopharmaceutical contract manufacturing market in the country is growing because, most of the pharma and biopharma companies are focusing to capitalize on the growth.

Asia Pacific is gaining attention among manufacturers for biologics production at reduced manufacturing cost. Emerging regions offering greater profit margins are major focus points for biopharmaceutical contract manufacturing, globally.”

Key Takeaways of Biopharmaceutical Contract Manufacturing Market Study

Although microbial-based platforms are abundantly used for the production of pharmaceuticals, mammalian-based cell culture is expected to gain traction during the forecast period, owing to higher efficiency and increasing demand.
In terms of product type, monoclonal antibodies currently hold a larger share of the biopharmaceutical contract manufacturing market, due to their superior efficacy as well as increasing adoption for the treatment of chronic diseases.
North America is anticipated to be the most lucrative region in the global biopharmaceutical contract manufacturing market, offering growth opportunities to market players.
The commercial application of biopharmaceutical contract manufacturing is expected to contribute a higher share as compared to clinical application by the end of 2029.

Key Market Players: